Table 2.
Participant demographic characteristics (full analysis set) per treatment group for participants in the two-dose cohort
Low-dose plus AF03 group (n=28) | Low-dose plus AS03 group (n=82) | High-dose plus AF03 group (n=27) | High-dose plus AS03 group (n=85) | High-dose plus unadjuvanted group (n=18) | Placebo group (n=29) | ||
---|---|---|---|---|---|---|---|
Aged 18–49 years | |||||||
Sex | .. | .. | .. | .. | .. | .. | |
Female | 9/18 (50%) | 25/54 (46%) | 11/17 (65%) | 23/54 (43%) | 10/18 (56%) | 8/18 (44%) | |
Male | 9/18 (50%) | 29/54 (54%) | 6/17 (35%) | 31/54 (57%) | 8/18 (44%) | 10/18 (56%) | |
Age, years | 35·3 (8·67) | 33·7 (8·99) | 32·5 (9·12) | 34·9 (8·77) | 34·8 (10·2) | 32·0 (8·41) | |
Race or ethnicity | .. | .. | .. | .. | .. | .. | |
White | 15/18 (83%) | 46/54 (85%) | 16/17 (94%) | 48/54 (89%) | 16/18 (89%) | 16/18 (89%) | |
Asian | 2/18 (11%) | 4/54 (7%) | 0/17 | 4/54 (7%) | 1/18 (6%) | 1/18 (6%) | |
Black or African American | 1/18 (6%) | 4/54 (7%) | 1/17 (6%) | 2/54 (4%) | 1/18 (6%) | 1/18 (6%) | |
American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | |
Hispanic or Latino | 4/18 (22%) | 9/54 (17%) | 2/17 (12%) | 6/54 (11%) | 3/18 (17%) | 3/18 (17%) | |
Aged 50 years or older | |||||||
Sex | .. | .. | .. | .. | .. | .. | |
Female | 5/10 (50%) | 11/28 (39%) | 7/10 (70%) | 21/31 (68%) | NA | 6/11 (55%) | |
Male | 5/10 (50%) | 17/28 (61%) | 3/10 (30%) | 10/31 (32%) | NA | 5/11 (45%) | |
Age, years | 58·8 (7·69) | 59·8 (6·53) | 58·7 (7·92) | 61·7 (7·86) | NA | 61·5 (4·41) | |
Race or ethnicity | .. | .. | .. | .. | .. | .. | |
White | 9/10 (90%) | 24/28 (86%) | 9/10 (90%) | 30/31 (97%) | NA | 10/11 (91%) | |
Asian | 1/10 (10%) | 3/28 (11%) | 0 | 0 | NA | 0 | |
Black or African American | 0 | 0 | 0 | 1/31 (3%) | NA | 1/11 (9%) | |
American Indian or Alaska Native | 0 | 1/28 (4%) | 0 | 0 | NA | 0 | |
Multiple | 0 | 0 | 1/10 (10%) | 0 | NA | 0 | |
Hispanic or Latino | 0 | 2/28 (7%) | 1/10 (10%) | 3/31 (10%) | NA | 0 |
Data are n/N (%) or mean (SD). NA=not applicable.